Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study-Reference-Cited by-同舟云学术

Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study

Published:2014-11 Issue:11 Volume:8 Page:1454-1463
ISSN:1873-9946
Container-title:Journal of Crohn's and Colitis
language:en
Short-container-title:Journal of Crohn's and Colitis

Author:

Ma Christopher,Huang Vivian,Fedorak Darryl K.,Kroeker Karen I.,Dieleman Levinus A.,Halloran Brendan P.,Fedorak Richard N.

Funder

Cecile Mactaggart Summer Student Research Fund

Center of Excellence For Gastrointestinal Inflammation and Immunity Research

Alberta Innovates Health Solutions IBD Consortium

University of Alberta Hospital Foundation

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,General Medicine

Link

http://academic.oup.com/ecco-jcc/article-pdf/8/11/1454/1020898/8-11-1454.pdf

Reference35 articles.

1. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial;Colombel;Gastroenterology,2007

2. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial;Hanauer;Lancet,2002

3. Infliximab maintenance therapy for fistulizing Crohn's disease;Sands;N Engl J Med,2004

4. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial;Sandborn;Gut,2007

5. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review;Gisbert;Am J Gastroenterol,2009

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-Cell Sequencing-Based Validation of T Cell-Associated Diagnostic Model Genes and Drug Response in Crohn’s Disease;International Journal of Molecular Sciences;2023-03-23

2. Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis;World Journal of Clinical Cases;2022-06-26

3. Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation;Clinical and Translational Gastroenterology;2022-04-01

4. Bioelectrical impedance analysis-based nomogram construction for predicting secondary loss of response to infliximab in bio-naïve Crohn’s disease patients;Biomedicine & Pharmacotherapy;2021-10

5. Predictors of drug survival: A cohort study comparing anti‐tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register;Alimentary Pharmacology & Therapeutics;2021-07-19